Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Zepp Health Corporation Reports Second Quarter 2021 Unaudited Financial Results


      News provided by

      Zepp Health Corp.

      Aug 19, 2021, 06:00 ET

      Share this article

      Share this article


      BEIJING, Aug. 19, 2021 /PRNewswire/ -- Zepp Health Corporation ("Zepp" or the "Company") (NYSE: ZEPP) today reported revenue of RMB1.8 billion (US$284.2 million), an increase of 61.4% from the same period last year; GAAP diluted net income per share of RMB0.35 (US$0.05); and GAAP diluted net income per ADS of RMB1.41 (US$0.22) for the second quarter ended June 30, 2021. Each ADS represents four (4) Class A ordinary shares.

      "We were pleased to top the high end of our guidance range for the second quarter, which included an 81% increase in our own Amazfit and Zepp branded product revenue and a 53% increase in revenue from products designed and built for Xiaomi," said Wang Huang, Chairman and CEO of Zepp Health. "Unit shipment volume for our own branded products grew 114% year-over-year in the second quarter, demonstrating continued expansion of our brands globally. Despite the drag of the pandemic on the industry, first half revenue from our own Amazfit and Zepp branded products increased 83% year-over-year, and in June, we were acknowledged by IDC that our Amazfit and Zepp smartwatch products have become one of the top four global adult smartwatch brands in its 2021Q1 report. Our confidence in the second half of 2021 is strengthend by the Company's announcements at our mid-July developers conference of our third generation proprietary smart watch chip, the Huangshan 2s; a new watch OS for third-party apps; and blood pressure monitoring algorithm on our watches; which will give our products new features and functionalities that will appeal to many consumers."

      Added Chief Financial Officer, Leon Deng, "Second quarter results reflected strong growth of the Company's own branded products, different timing this year for launch of Xiaomi's new Mi Band product, easing of Covid restrictions in some geographies during the quarter, and continued expense control, all driving revenue growth and profitability."

      Second Quarter 2021 Financial Summary










      For the Three Months Ended


      For the Six Months Ended

      GAAP in millions, except for percentages and per share/ADS amounts


      June 30,  

      2021

      June 30,

      2020[1]


      June 30,  

      2021

      June 30,   

      2020[1]

      Revenue RMB


      1,835.1

      1,137.3


      2,982.4

      2,225.7

      Revenue USD


      284.2

      161.0


      461.9

      315.0

      Gross Margin


      22.0%

      22.3%


      22.2%

      22.4%

      Net income attributable to Zepp Health Corporation RMB


      92.6

      13.3


      52.1

      32.5

      Adjusted net income attributable to Zepp Health Corporation RMB[2]


      132.5

      19.1


      103.4

      44.7








      Diluted net income per share RMB


      0.35

      0.05


      0.20

      0.13

      Diluted net income per ADS USD


      0.22

      0.03


      0.12

      0.07

      Adjusted diluted net income per share RMB[3]


      0.50

      0.07


      0.39

      0.17

      Adjusted diluted net income per ADS USD


      0.31

      0.04


      0.24

      0.10

      Units Shipped


      11.5

      8.9


      17.8

      16.5

      [1] The USD numbers in 2020 are referenced with the prior 6-K disclosures.

      [2] Adjusted net income attributable to Zepp Health Corporation is a non-GAAP measure, which excludes share-based compensation expenses. See "Reconciliation of GAAP and Non-GAAP Results" at the end of this press release.

      [3] Adjusted diluted net income is the abbreviation of Adjusted net income attributable to Zepp Health Corporation, which is a non-GAAP measure and excludes share-based compensation expenses attributable to Zepp Health Corporation, and is used as the numerator in computation of adjusted basic and diluted net income per ADS attributable to Zepp Health Corporation.

      Second Quarter 2021 Financial Results

      Revenue

      Total units shipped in the second quarter of 2021 increased by 29.2% year-over-year to 11.5 million, compared with 8.9 million in the second quarter of 2020. This was driven by a 114.3% increase in unit shipments of Amazfit and Zepp-branded products and a 22.0% increase in unit shippments of Xiaomi wearable products.

      Revenues for the second quarter of 2021 reached RMB1.8 billion (US$284.2 million), an increase of 61.4% from the second quarter of 2020. In the second quarter of 2021, revenue from both Xiaomi wearable products and from self-branded products increased compared with the same period in 2020, primarily driven by the launch of Mi Band 6 and sales of the Company's popular premium GT series, basic Bip and Pop models and rugged T-Rex.

      Both sequential and year-over-year quarterly revenue changes can be affected by fluctuations in seasonal purchase patterns as well as by timing of new product introductions. The Company launched Mi Band 6 in the April of 2021 and Mi Band 5 in June of 2020.

      Impact of COVID-19 on Our Business

      The global impact of the COVID-19 pandemic continued in the second quarter 2021, although abating in varying degrees in different markets as vaccinations became more widely available and some restrictions were lifted. However, given the current state of the COVID-19 virus mutation at the time of this release, the Company cannot predict the potential, if any, future negative impact on market conditions or the Company's operations. 

      Gross Margin

      Gross margin in the second quarter of 2021 was 22.0%, compared with 22.3% in the same period of 2020. The gross margins on self-branded products are generally higher than Xiaomi wearable products. In line with previous Mi Band product launches, the newly introduced Mi Band 6 in this quarter accounted for a larger increase in Xiaomi unit volume shipped in the quarter. Gross margin and gross profit are affected by product mix as different products have different margin contributions. These changes can also be influenced by the stage of the product in its lifecycle, product iterations and new product introductions.  

      Research & Development

      Research and development expense in the second quarter of 2021 was RMB160.3 million, increasing 36.8% year-over year, and comprising 8.7% of revenue, versus 10.3% in the same period last year. The increase was primarily driven by increased investment in R&D talents associated with developing new core proprietary technologies and new products. 

      Sales & Marketing

      Sales and Marketing expense in the second quarter of 2021 was RMB104.7 million, increasing 46.7% year-over-year, and comprising 5.7% of revenue, compared with 6.3% of revenue in the same period in 2020. The increase was driven by higher salary and wages costs for marketing and sales personnel as well as advertising and promotional expenses to expand product recognition globally.

      General & Administrative

      General and Administrative expense was RMB66.4 million in the second quarter of 2021, increasing 19.9% year-over-year, and comprising 3.6% of revenue, compared with 4.9% in the same period in 2020. The increase was mainly attributable to higher personel compensation costs for retaining current employees to support company's long-term growth together.

      Operating Expenses and Net Income

      Total Operating Expense for the second quarter of 2021 was RMB331.4 million, an increase of RMB87.5 million from the same period in 2020, comprising 18.1% of revenue, compared with 21.5% in the second quarter of 2020. 

      Beginning in the third quarter of 2020, the Company adopted a balanced approach to expense control while still maintaining an investment priority in new technologies, new product development and global growth capabilities.

      The operating expenses increase was mainly attributed to share-base compensation. In the second quarter 2021, the company granted a new batch of restricted shares and options with 4 to 5-year vested period to the employees, causing a RMB34 million increase to total operating expenses, with the aim to motivate its employees to work together toward long-term strategic goal of the Company.

      Operating income for the second quarter of 2021 was RMB71.6 million, an increase of 660.8% from RMB9.4 million for the same period in 2020.

      Net income attributable to Zepp Health Corporation for the second quarter of 2021 was RMB92.6 million, compared with RMB13.3 million in the second quarter of 2020. The increase was partially attributable to RMB13.5 million investment income and RMB24.8 net income from equity method investments.

      Liquidity and Capital Resources

      As of June 30, 2021, the Company had cash and cash equivalents of RMB1,392.6 million (US$215.7 million), compared with RMB2,649.2 million as of June 30, 2020, and RMB1,090.5 million as of March 31, 2021.

      Outlook

      For the third quarter of 2021, the management of the Company currently expects:

      -  Net revenues to be between RMB1.6 billion and RMB1.8 billion, compared with RMB2.2 billion in the third quarter of 2020. 

      This outlook reflects continuing uncertainty pertaining to the potential affects of the COVID-19 pandemic on sales and on electronic component delays, as well as expected sales seasonality of both self-branded and Xiaomi products. It is based on the current market conditions and reflects the Company management's current and preliminary estimates of market and operating conditions and customer demand, which are all subject to change.

      Conference Call

      The Company's management will hold a conference call at 8:00 a.m. Eastern Time on Thursday, August 19, 2021 (8:00 p.m. Beijing Time on August 19, 2021) to discuss financial results and answer questions from investors and analysts. Listeners may access the call by dialing:

      US (Toll Free):

      +1-888-346-8982

      International:

      +1-412-902-4272

      Mainland China (Toll Free):

      400-120-1203

      Hong Kong (Toll Free):

      800-905-945

      Hong Kong:

      +852-3018-4992

      Participants should dial-in at least 10 minutes before the scheduled start time and ask to be connected to the call for "Zepp Health Corporation."

      Additionally, a live and archived webcast of the conference call will be available at https://ir.zepp.com/investor.

      A telephone replay will be available one hour after the call until August 26, 2021 by dialing:

      About Zepp Health Corporation (NYSE: ZEPP)

      US Toll Free:


      +1-877-344-7529

      International:


      +1-412-317-0088

      Replay Passcode:


      10159349

      Zepp Health changed its name from Huami Corporation (HMI) on February 25, 2021 to emphasize its health focus with a name that resonates across languages and cultures globally. The Company's mission continues to be connecting health with technology. Since its inception in 2013, Zepp Health has developed a platform of proprietary technology including AI chips, biometric sensors, and data algorithms, which drive a broadening line of smart health devices for consumers, and data analytics services for population health. Zepp Health is one of the largest global developers of smart wearable health and consumer fitness devices, shipping 46 million units in 2020. Zepp Health Corporation is based in Hefei, China, with U.S. operations, Zepp Health USA, based in Cupertino, Calif..

      Use of Non-GAAP Measures

      We use adjusted net income, a non-GAAP financial measure, in evaluating our operating results and for financial and operational decision-making purposes. Adjusted net income represents net income excluding share-based compensation expenses, and such adjustment has no impact on income tax. Adjusted net income attributable to Zepp Health Corporation is a non-GAAP measure, which excludes share-based compensation expenses attributable to Zepp Health Corporation, and is used as the numerator in computation of adjusted net income per share and per ADS attributable to Zepp Health Corporation.

      We believe that adjusted net income and adjusted net income attributable to Zepp Health Corporation help identify underlying trends in our business that could otherwise be distorted by the effect of certain expenses that we include in net income and net income attributable to Zepp Health Corporation. We believe that adjusted net income and adjusted net income attributable to Zepp Health Corporation provides useful information about our operating results, enhances the overall understanding of our past performance and future prospects and allows for greater visibility with respect to key metrics used by our management in its financial and operational decision-making.

      Adjusted net income and adjusted net income attributable to Zepp Health Corporation, should not be considered in isolation or construed as an alternative to net income, basic and diluted net income per share and per ADS attributable to Zepp Health Corporation. or any other measure of performance or as an indicator of our operating performance. Investors are encouraged to review the historical non-GAAP financial measures to the most directly comparable GAAP measures. Adjusted net income and adjusted net income attributable to ordinary shareholders, presented here may not be comparable to similarly titled measures presented by other companies. Other companies may calculate similarly titled measures differently, limiting their usefulness as comparative measures to our data. We encourage investors and others to review our financial information in its entirety and not rely on a single financial measure.

      Exchange Rate

      The Company's business is primarily conducted in China and the significant majority of revenues generated are denominated in RMB. This announcement contains currency conversions of RMB amounts into US$ solely for the convenience of the reader. Unless otherwise noted, all translations from RMB to US$ are made at a rate of RMB6.4566 to US$1.00, the effective noon buying rate for June 30, 2021 as set forth in the H.10 statistical release of the Federal Reserve Board. No representation is made that the RMB amounts could have been, or could be, converted, realized or settled into US$ at that rate on June 30, 2021, or at any other rate.

      Safe Harbor Statement

      This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the cooperation with Xiaomi, the recognition of the Company's self-branded products; the Company's growth strategies; trends and competition in global wearable technology market; changes in the Company's revenues and certain cost or expense accounting policies; governmental policies relating to the Company's industry and general economic conditions in China and the global. Further information regarding these and other risks is included in the Company's filings with the United States Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.

      For investor and media inquiries, please contact:

      In China:
      Zepp Health Corporation
      Grace Yujia Zhang
      Email: [email protected]

      The Piacente Group, Inc.
      Yang Song
      Tel: +86-10-6508-0677
      Email: [email protected]

      In the United States:
      Zepp Health Corporation
      Brad Samson
      Tel: 1+714-955-3951
      Email: [email protected]  

      Zepp Health Corporation

      UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

      (Amounts in thousands of Renminbi ("RMB") and U.S. dollars ("US$")

      except for number of shares and per share data, or otherwise noted)




      As of December 31,


      As of June 30,



      2020


      2021



      RMB


      RMB


      US$








      Assets







      Current assets:







      Cash and cash equivalents


      2,273,349


      1,392,572


      215,682

      Restricted cash


      2,401


      1,418


      220

      Term deposit


      5,000


      5,000


      774

      Accounts receivable


      298,038


      422,346


      65,413

      Amounts due from related parties, current


      860,213


      913,451


      141,476

      Inventories, net


      1,217,537


      1,305,510


      202,198

      Short-term investments


      18,430


      19,045


      2,950

      Prepaid expenses and other current assets


      152,898


      152,801


      23,666

      Total current assets


      4,827,866


      4,212,143


      652,379








      Property, plant and equipment, net


      124,619


      149,308


      23,125

      Intangible asset, net


      145,213


      139,245


      21,566

      Goodwill


      62,515


      61,860


      9,581

      Long-term investments


      443,986


      1,512,922


      234,322

      Deferred tax assets


      120,190


      136,361


      21,120

      Other non-current assets


      28,165


      20,094


      3,112

      Non-current operating lease right-of-use assets


      151,165


      129,816


      20,106

      Total assets


      5,903,719


      6,361,749


      985,311


      Zepp Health Corporation

      UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

      (Amounts in thousands of Renminbi ("RMB") and U.S. dollars ("US$")

      except for number of shares and per share data, or otherwise noted)




      As of December 31, 


      As of June 30,



      2020


      2021



      RMB


      RMB


      US$








      Liabilities







      Current liabilities:







      Accounts payable


      1,951,335


      1,465,456


      226,970

      Advance from customers


      42,502


      31,336


      4,853

      Amount due to related parties, current


      11,185


      23,028


      3,567

      Accrued expenses and other current liabilities


      252,275


      204,221


      31,630

      Income tax payables


      27,706


      15,014


      2,325

      Notes payable


      -


      4,525


      701

      Short-term bank borrowings


      504,671


      687,789


      106,525

      Total current liabilities


      2,789,674


      2,431,369


      376,571

      Deferred tax liabilities


      22,374


      25,870


      4,007

      Long-term borrowing


      60,000


      727,395


      112,659

      Other non-current liabilities


      185,168


      240,915


      37,313

      Non-current operating lease liabilities


      116,245


      94,698


      14,667

      Total liabilities


      3,173,461


      3,520,247


      545,217

      Zepp Health Corporation


      UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS


      (Amounts in thousands of Renminbi ("RMB") and U.S. dollars ("US$")


      except for number of shares and per share data, or otherwise noted)











      As of December 31,


      As of June 30,



      2020


      2021



      RMB


      RMB


      US$








      Equity







      Ordinary shares


      157


      158


      24

      Additional paid-in capital


      1,552,109


      1,613,095


      249,837

      Accumulated retained earnings


      1,133,368


      1,185,510


      183,612

      Accumulated other comprehensive income


      44,624


      38,712


      5,997

      Total Zepp Health Corporation shareholders' equity


      2,730,258


      2,837,475


      439,470

      Noncontrolling interests


      -


      4,027


      624

      Total equity


      2,730,258


      2,841,502


      440,094

      Total liabilities and equity


      5,903,719


      6,361,749


      985,311

      Zepp Health Corporation

      UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

      (Amounts in thousands of Renminbi ("RMB") and U.S. dollars ("US$")

      except for number of shares and per share data, or otherwise noted)












      For the Three Months Ended June 30,



      2020


      2021



      RMB


      RMB


      US$








      Revenues


      1,137,274


      1,835,141


      284,227

      Cost of revenues


      (883,891)


      (1,432,105)


      (221,805)

      Gross profit


      253,383


      403,036


      62,422

      Operating expenses:







      Selling and marketing


      (71,342)


      (104,686)


      (16,214)

      General and administrative


      (55,423)


      (66,448)


      (10,291)

      Research and development


      (117,207)


      (160,304)


      (24,828)

      Total operating expenses


      243,972


      331,438


      51,333

      Operating income


      9,411


      71,598


      11,089

      Other income and expenses:







      Investment income


      -


      13,507


      2,092

      Interest income


      13,667


      4,525


      701

      Interest expense


      (8,049)


      (10,342)


      (1,602)

      Other income/(expenses), net


      9,186


      (216)


      (33)

      Income before income tax and income from equity
      method investment


      24,215


      79,072


      12,247

      Income tax expenses


      (2,486)


      (11,607)


      (1,798)

      Income before (loss)/income from equity method investments


      21,729


      67,465


      10,449

      Net (loss)/income from equity method investments


      (7,611)


      24,836


      3,847

      Net income


      14,118


      92,301


      14,296

      Less: Net income/(loss) attributable to noncontrolling interest


      811


      (269)


      (42)

      Net income attributable to Zepp Health Corporation


      13,307


      92,570


      14,338

      Net income per share attributable to Zepp Health Corporation 







      Basic income per ordinary share


      0.05


      0.37


      0.06

      Diluted income per ordinary share


      0.05


      0.35


      0.05








      Net income per ADS (4 ordinary shares equal to 1 ADS)







      ADS – basic


      0.21


      1.47


      0.23

      ADS – diluted


      0.21


      1.41


      0.22








      Weighted average number of shares used in computing net income
      per share







      Ordinary share – basic


      247,828,507


      251,813,617


      251,813,617

      Ordinary share – diluted


      259,364,320


      263,499,745


      263,499,745

      Zepp Health Corporation

      Reconciliation of GAAP and Non-GAAP Results

      (Amounts in thousands of Renminbi ("RMB") and U.S. dollars ("US$")

      except for number of shares and per share data, or otherwise noted)










      For the Three Months Ended June 30,



      2020


      2021



      RMB


      RMB


      US$








      Net income attributable to Zepp Health Corporation


      13,307


      92,570


      14,338

      Share-based compensation expenses


      5,835


      39,922


      6,183

      Adjusted net income attributable to Zepp Health
      Corporation [2]


      19,142


       

      132,492


       

      20,521








      Adjusted net income per share attributable to 
      Zepp Health Corporation







      Adjusted basic income per ordinary share


      0.08


      0.53


      0.08

      Adjusted diluted income per ordinary share


      0.07


      0.50


      0.08








      Adjusted net income per ADS (4 ordinary shares equal
      to 1 ADS)







      ADS – basic


      0.31


      2.10


      0.33

      ADS – diluted


      0.30


      2.01


      0.31








      Weighted average number of shares used in 
      computing adjusted net income per share







      Ordinary share – basic


      247,828,507


      251,813,617


      251,813,617

      Ordinary share – diluted


      259,364,320


      263,499,745


      263,499,745








      Share-based compensation expenses included 
      are follows:







      Cost of revenues


      (61)


      -


      -

      Selling and marketing


      632


      6,860


      1,062

      General and administrative


      3,833


      6,003


      930

      Research and development


      1,431


      27,059


      4,191

      Total


      5,835


      39,922


      6,183

      Zepp Health Corporation

      UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

      (Amounts in thousands of Renminbi ("RMB") and U.S. dollars ("US$")

      except for number of shares and per share data, or otherwise noted)












      For the Six Months Ended June 30,



      2020


      2021



      RMB



      RMB



      US$










      Revenues


      2,225,735


      2,982,404


      461,916

      Cost of revenues


      (1,727,792)


      (2,321,163)


      (359,502)

      Gross profit


      497,943


      661,241


      102,414

      Operating expenses:







      Selling and marketing


      (126,185)


      (195,473)


      (30,275)

      General and administrative


      (106,306)


      (131,733)


      (20,403)

      Research and development


      (235,543)


      (312,634)


      (48,421)

      Total operating expenses


      468,034


      639,840


      99,099

      Operating income


      29,909


      21,401


      3,315

      Other income and expenses:







      Investment income


      -


      13,507


      2,092

      Interest income


      21,338


      10,253


      1,588

      Interest expense


      (8,773)


      (16,990)


      (2,631)

      Other income, net


      755


      2,285


      354

      Gain from fair value change of long-term investment


      1,293


      -


      -

      Income before income tax and income from equity method
      investment


      44,522


      30,456


      4,718

      Income tax expenses


      (4,519)


      (4,009)


      (621)

      Income before loss from equity method investments


      40,003


      26,447


      4,097

      Net (loss)/income from equity method investments


      (7,943)


      25,293


      3,917

      Net income


      32,060


      51,740


      8,014

      Less: Net loss attributable to noncontrolling interest


      (415)


      (403)


      (62)

      Net income attributable to Zepp Health Corporation


      32,475


      52,143


      8,076

      Net income per share attributable to Zepp Health Corporation







      Basic income per ordinary share


      0.13


      0.21


      0.03

      Diluted income per ordinary share


      0.13


      0.20


      0.03








      Net income per ADS (4 ordinary shares equal to 1 ADS)







      ADS – basic


      0.52


      0.83


      0.13

      ADS – diluted


      0.50


      0.79


      0.12








      Weighted average number of shares used in computing net
      income per share







      Ordinary share – basic


       

      247,742,838


      251,306,762


      251,306,762

      Ordinary share – diluted


      259,456,193


      263,397,411


      263,397,411

      Zepp Health Corporation

      Reconciliation of GAAP and Non-GAAP Results

      (Amounts in thousands of Renminbi ("RMB") and U.S. dollars ("US$")

      except for number of shares and per share data, or otherwise noted)






      For the Six Months Ended June 30,



      2020


      2021



      RMB


      RMB


      US$








      Net income attributable to Zepp Health Corporation


      32,475


      52,143


      8,076

      Share-based compensation expenses


      12,213


      51,300


      7,946

      Adjusted net income attributable to Zepp Health
      Corporation [2]


      44,688


       

      103,443


       

      16,022








      Adjusted net income per share attributable to 
      Zepp Health Corporation







      Adjusted basic income per ordinary share


      0.18


      0.41


      0.06

      Adjusted diluted income per ordinary share


      0.17


      0.39


      0.06








      Adjusted net income per ADS (4 ordinary shares equal
      to 1 ADS)







      ADS – basic


      0.72


      1.65


      0.26

      ADS – diluted


      0.69


      1.57


      0.24








      Weighted average number of shares used in 
      computing adjusted net income per share







      Ordinary share – basic


      247,742,838


      251,306,762


      251,306,762

      Ordinary share – diluted


      259,456,193


      263,397,411


      263,397,411








      Share-based compensation expenses included 
      are follows:







      Cost of revenues


      (54)


      -


      -

      Selling and marketing


      1,264


      7,020


      1,087

      General and administrative


      7,930


      14,221


      2,203

      Research and development


      3,073


      30,059


      4,656

      Total


      12,213


      51,300


      7,946


      SOURCE Zepp Health Corp.

      Modal title

      Also from this source

      Zepp Health Corporation to Report Third Quarter 2026 Financial Results on November 22, 2026

      Zepp Health Corporation ("Zepp Health" or the "Company") (NYSE: ZEPP), a global leader in smart wearables and health technology, today announced that ...

      Zepp Health Corporation Reports Second Quarter of 2026 Unaudited Financial Results

      Zepp Health Corporation (NYSE: ZEPP) ("Zepp", the "Company" or "we") today announced its unaudited financial results for the second quarter of 2026....

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Biometrics

      Biometrics

      Consumer Electronics

      Consumer Electronics

      Computer & Electronics

      Computer & Electronics

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.